Trial Profile
Evaluation of the Efficacy and Safety of Flebogamma 5% DIF [Immune Globulin Intravenous (Human)] for Replacement Therapy in Pediatric Subjects With Primary Immunodeficiency Diseases.
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 02 Jan 2018
Price :
$35
*
At a glance
- Drugs Immune globulin (Primary)
- Indications Immunodeficiency disorders
- Focus Therapeutic Use
- 02 Jan 2018 New trial record